• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Agile Therapeutics Inc.

    8/28/24 12:15:03 AM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRX alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: August 27, 2024
    Accession Number: 0001104659-24-092916
    Submission Type: POS AM
    CIK: 0001261249
    Company Name: AGILE THERAPEUTICS INC
    File Number: 333-264960
    Get the next $AGRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGRX

    DatePrice TargetRatingAnalyst
    11/3/2021$3.50 → $2.50Buy
    HC Wainwright & Co.
    9/13/2021$7.00 → $3.50Buy
    HC Wainwright & Co.
    7/27/2021$6.00 → $5.00Outperform
    RBC Capital
    More analyst ratings